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Previewshypomethylation phenotype. The poten-
tial role for Stat5 in guiding Tet binding
to the Foxp3 locus is of particular interest
given recent findings demonstrating that
IL-2 sensing and Stat5 interactions with
the CNS2 region are important for the
maintenance of Treg cell identity (Feng
et al., 2014).
Acquisition of the proper epigenetic
modifications is critical for the establish-
ment of a stable Treg cell lineage, and
elucidating the signals and molecular
mechanisms that regulate the Treg cell
epigenome are of fundamental impor-
tance. The findings reported by Yang
et al. (2015) provide novel insight into
how signaling by the gasotransmitter
H2S influences DNA demethylation of
key Foxp3 regulatory regions. The pro-
duction of H2S requires substrates gener-ated by the metabolism of methionine,
indicating a role for nutrient sensing in
regulating the Treg cell epigenome. In
the context of previous work in the field,
these findings indicate that the integration
of environmental signals (antigen, cyto-
kine, and nutrients) allows for the dynamic
regulation of Treg cell identity. Indeed,
the tunable nature of these signals might
allow for more precise regulation of Treg
cell identity and function.
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Inhibition of the inflammasome might be beneficial for numerous inflammatory pathologies. In this issue
of Immunity, de Almeida et al. (2015) report that the PYRIN domain-only protein (POP1) efficiently inhibits
inflammasome activation, identifying it as a pan-inflammasome inhibitor.In recent years the inflammasome and
interleukin 1 (IL-1) signaling have been
centrally implicated in many human pa-
thologies. This includes a wide range
of chronic inflammatory disorders such
as diabetes, atherosclerosis, rheumatoid
arthritis, and obesity, among others
(Guo et al., 2015). In addition to these
multifactorial chronic disorders, cryopyri-
nopathies (Cryopyrin-associated periodic
syndromes [CAPS]) are the result of
mutations that cause constitutive inflam-
masome activation and unchecked IL-1
signaling (Broderick et al., 2015). This
has led to an explosion of clinical trials
based on inhibiting IL-1-mediated pathol-
ogies, including the use of an IL-1 recep-
tor antagonist (Anakinra/Kineret), an IL-1receptor decoy (Rilanocept), and various
monoclonal antibodies against IL-1b
(Dinarello et al., 2012; Guo et al., 2015).
In addition to these therapeutic modal-
ities, new small molecule inhibitors target-
ing various steps in the inflammasome
pathway have been developedwith prom-
ising results (Guo et al., 2015). Many of
these therapeutics target signaling down-
stream of IL-1, and even those that target
upstream events such as inflammasome
activation generally target only a specific
type of inflammasome rather than all in-
flammasomes (Guo et al., 2015).
The inflammasome is a multi-compo-
nent structure, which, when formed, acti-
vates caspase-1, which in turn can cleave
the inactive precursors of specific pro-inflammatory cytokines (mainly IL-1b and
IL-18), thereby activating them and lead-
ing to their secretion (Guo et al., 2015).
The best studied of the inflammasomes,
and the one targeted by most current
therapeutics, is the nucleotide binding
domain and leucine-rich repeat (NLR)
pyrin domain containing 3 (NLRP3) in-
flammasome, which, not coincidently, is
associated with the largest number of
inflammasome-mediated diseases (Guo
et al., 2015; Man and Kanneganti, 2015).
The NLRP3 inflammasome responds to
many diverse danger signals including,
but not limited to, extracellular ATP, crys-
tals and other insoluble particles, and
bacterial toxins (Guo et al., 2015; Man
and Kanneganti, 2015). Although not, August 18, 2015 ª2015 Elsevier Inc. 213
Figure 1. Mechanisms of Inflammasome Inhibition
Left: POP1 binds to the PYD of ASC and prevents PYD-PYD interactions between ASC and NLRP3.
Right: multiple inflammasome inhibitory mechanisms are shown, including POP1.
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Previewsfully elucidated, these dangers signals
all seem to converge at a central hub
involving mitochondria and/or K+ efflux
(Guo et al., 2015; Man and Kanneganti,
2015). Additionally, lysosomal disruption
can lead to NLRP3 activation, but whether
or not this is independent of mitochon-
drial/K+ involvement is not well under-
stood (Guo et al., 2015; Man and
Kanneganti, 2015). Other common NLR
inflammasomes include NLRP1 and
NLRC4, which respond to certain bacte-
rial toxins and flagellin, respectively (Guo
et al., 2015; Man and Kanneganti, 2015).
Additionally, the AIM2 inflammasome ac-
tivates caspase-1 in response to bacterial
DNA (Guo et al., 2015; Man and Kanne-
ganti, 2015).
Inflammasome assembly requires mul-
tiple components being recruited in an
ordered structure with prion-like growth
properties (Guo et al., 2015;Man andKan-
neganti, 2015). In the case of NLRP3,
the key adaptor molecule ASC bridges
the gap between NLRP3 and Caspase-1
by binding to their PYRIN and CARD
domains, respectively (Guo et al., 2015;
Man and Kanneganti, 2015). ASC is also
required for both the AIM2 and NLRP1 in-
flammasome activation in a similar capac-
ity (Guo et al., 2015; Man and Kanneganti,214 Immunity 43, August 18, 2015 ª2015 Els2015). Interestingly, although NLRC4 has
its own CARD domain and therefore theo-
retically doesn’t require ASC to bind Cas-
pase-1, new data suggest that ASCmight
still be required for full activation (Guo
et al., 2015). Thus, ASC plays a central
role in inflammasome activation, and its
inhibition could affect multiple inflamma-
some pathways.
In the article by de Almeida et al. (2015)
appearing in this issue of Immunity, the
authors have identified PYRIN (PYD) only
protein (POP1) as a negative regulator
of inflammasome activation. Although
the POP family of proteins was identi-
fied in humans more than 10 years ago
(they are not found in mice) and includes
POP1 (also known as ASC2), POP2,
POP3, andPOP4 (Stehlik et al., 2003), their
functions have been unclear. Recently,
POP3 was found to interact with AIM2
and inhibit AIM2 inflammasome activation
(Khare et al., 2014). POP1was initially sus-
pected to enhance NLRP3 inflammasome
activation (Stehlik et al., 2003), but more
recently Atianand and Harton (2011) re-
ported that POP1 does not alter either
ASC or NLRP3 processing of IL-1b. Thus,
the function of POP1 remained contro-
versial. However, the current work by
de Almeida et al. (2015) now clearlyevier Inc.demonstrates that POP1 knockdown
promotes LPS-induced IL-1b secretion in
both THP1 cells and primary human mac-
rophages. The authors showed by immu-
noprecipitation that POP1, which con-
tains a PYRIN domain but lacks a CARD
domain, prevented NLRP3 from inter-
acting with ASC, thus inhibiting inflam-
masome oligomerization (Figure 1, left).
Consistent with this, POP1 expression
diminished IL-1b secretion in response to
LPS. Importantly, the inhibitory effects of
POP1 were observed not only for
NLRP3, but also for AIM2 and NLRC4 in-
flammasome activation. Despite the fact
that NLRC4 has its own CARD domain,
which can bind to caspase-1 directly,
POP1 inhibited flagellin-driven inflam-
masome activation. This suggests that
ASC is required for full NLRC4-driven
inflammasome activation by stabilizing
the structure, as has been reported pre-
viously (Guo et al., 2015). Furthermore,
the authors found that POP1 overex-
pression inhibited ASC particle release,
thereby preventing secondary inflamma-
some activation after engulfment by
macrophages. de Almeida et al. (2015)
generated transgenic mice expressing
human POP1 under the macrophage-
specific CD68 promoter and showed
that NLRP3 inflammasome autoactiva-
tion by CAPS mutation was significantly
inhibited. More importantly, these mice
were protected against LPS-induced
peritonitis.
The authors also found that POP1
was regulated in an NF-kB-dependent
manner, suggesting that its expression in
human macrophages is part of a feed-
back inhibitory loop. Considering the
number and variety of chronic inflamma-
tory disorders mediated by IL-1 signaling,
it is not surprising that the inflammasome
and IL-1 signaling are tightly regulated
(Dorfleutner et al., 2015; Guo et al.,
2015; Man and Kanneganti, 2015).
Endogenously, we have evolved many
checkpoints and feedback mechanisms
to prevent overactive immune signaling,
especially through the inflammasome
and/or IL-1 signaling pathway (Figure 1,
right). This includes two-step activation
of the inflammasome, autophagy in oppo-
sition to NLRP3 activation, ASC phos-
phorylation, IL-1 receptor antagonist and
IL-1 receptor 2, alternatively spliced prod-
ucts such asMyD88s, and A20 ubiquitina-
tion of TRAF6, among others (Garlanda
Immunity
Previewset al., 2013; Guo et al., 2015). The authors’
investigation into the inhibitory activity
of POP1 is especially important because
their data suggest that POP1 inhibits
all the major inflammasomes (NLRP3,
NLRC4, and AIM2), thus having a broad
anti-inflammatory effect.
The authors found that POP1 was regu-
lated by NF-kB in human macrophages,
but it is intriguing that they also observed
that POP1 was downregulated in CAPS
patients, which seems counter-intuitive
but might explain why CAPS patients are
highly susceptible to increased systemic
autoinflammation. Although the authors
suggest that these patients might also
have a deleterious mutation leading to
POP1 downregulation, the likelihood for
these patients to have a loss-of-function
SNP for POP1 in addition to the gain-of-
function SNP in NLRP3 seems low and
will require further study. More likely,
other as-yet-to-be-discovered feedback
mechanisms are at play that leads to
reduction in POP1 expression in CAPS
and sepsis patients. Importantly, this
novel finding led the authors to generate
a fusion protein of POP1 and the HIV
peptide TAT that could be delivered into
any cell with the promise that it would
target and inhibit the activation of all the
inflammasomes. Indeed, mice given the
TAT-POP1 fusion protein intraperitone-
ally were protected against LPS-induced
peritonitis.
The work by de Almeida et al. (2015)
provides compelling evidence for a
new feedback regulatory loop to con-
trol excessive inflammasome activa-
tion. However, more work remains to
be done; the endogenous regulation of
POP1 is still unclear, and questions
remain as to why CAPS patients down-regulate POP1 expression. In addition to
POP1, human cells also possess four
ASC alternatively-spliced isoforms (ASC,
ASC-b, ASC-c, and ASC-d), whereas
mouse macrophages have only ASC and
ASC-c (Dorfleutner et al., 2015). In
contrast to ASC and ASC-b, ASC-c is
structurally missing part of the PYD and
functions as an inhibitor of inflammasome
activation. Further studies are required to
better understand how POPs regulate in-
flammasome activation and if and how
ASC alternative splicing might further
fine-tune the control of inflammasome
activation.
The use of TAT-POP1 as a potential
novel therapeutic has tremendous trans-
lational value and is very appealing.
Fusing the HIV TAT peptide to the protein
of choice allows for efficient entry into
mammalian cells. Because POP1 theo-
retically targets all of the inflammasomes
that require ASC, this makes POP1 an
attractive candidate as a powerful pan-
inflammasome inhibitor for numerous
inflammatory diseases. Although most
attempts at disrupting the inflamma-
some-induced inflammatory pathologies
have targeted downstream IL-1 signaling,
newer small molecule inhibitors working
upstream are currently being evaluated
(Guo et al., 2015; Man and Kanneganti,
2015). Attempts to develop therapeutics
based on caspase-1-specific peptido-
mimetic inhibitors (pralnacasan and
VX-765) based on the YVAD tetrapeptide
sequence are providing mixed results
because of liver toxicity. Other new in-
hibitors target only a specific inflamma-
some (i.e., NLRP3) (Guo et al., 2015;
Man and Kanneganti, 2015). Therefore,
TAT-POP1, which seems to be a pan-
inflammasome inhibitor, might provideImmunity 43an advantage and have greater clinical
utility. Additionally, unlike therapeutics
that target IL-1 signaling, interfering
with inflammasome activation is a more
proximal event and is likely to lead to
greater protection. Indeed, inflamma-
some activation is often associated with
cell death (pyroptosis and/or apoptosis)
and POP1 efficiently prevented cell
death in addition to inhibiting inflamma-
some activation. Thus, the best way to
cool down inflammation might be with a
POP1(sicle).REFERENCES
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